Provided by Tiger Trade Technology Pte. Ltd.

KEYMED BIO-B

73.050
-0.500-0.68%
Volume:2.62M
Turnover:191.18M
Market Cap:21.84B
PE:-38.25
High:74.800
Open:73.500
Low:71.000
Close:73.550
52wk High:89.750
52wk Low:44.660
Shares:299.00M
HK Float Shares:299.00M
Volume Ratio:1.75
T/O Rate:0.88%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-1.910
ROE:21.49%
ROA:-8.24%
PB:4.66
PE(LYR):-38.25
PS:22.37

Loading ...

KeyMed Biosciences Announces 2026 H1 Results and Business Updates

THOMSON REUTERS
·
Aug 20

Press Release: Keymed Biosciences Announces 2026 H1 Results and Business Updates

Dow Jones
·
Aug 20

Historic Breakthrough in mRNA Cancer Vaccines: E Fund Biotech ETF (03186) Taps Innovation Opportunities Across Hong Kong and US Markets

Stock News
·
Aug 20

KEYMED BIO-B Surges Over 6% Pre-Market as H1 Drug Sales Climb 132%

Deep News
·
Aug 20

Movement Alert|KEYMED BIO-B Rises 6.16% in Regular Trading, Proposed STAR Market Listing Combined with H1 Profit Turnaround

Market Focus
·
Aug 20

Keymed Biosciences Announces Plan for RMB Share Issue and STAR Market Listing

Bulletin Express
·
Aug 19

KEYMED BIO-B (02162) Announces Proposed RMB Share Issuance for STAR Market Listing

Stock News
·
Aug 19

Keymed Biosciences Plans RMB Share Listing on Shanghai STAR Market

Reuters
·
Aug 19

KeyMed Biosciences - no Application Made to Regulatory Authorities for RMB Share Issue as of Aug 19, 2026

THOMSON REUTERS
·
Aug 19

KeyMed Biosciences - Proposes RMB Share Issue for Sci-Tech Board Listing

THOMSON REUTERS
·
Aug 19

Keymed Biosciences Swings to FY26 H1 Profit of RMB 1.22 Billion; Revenue Rises 24% to RMB 617.07 Million

Reuters
·
Aug 19

KeyMed Biosciences H1 Revenue RMB 617.068 Million

THOMSON REUTERS
·
Aug 19

Keymed Biosciences (SEHK:2162) Hits A Phase III Milestone, Is The Upside Already Priced In?

Simply Wall St.
·
Aug 10

Keymed Bio-B (02162) Announces Phase II Trial Success for CM512 in Chronic Sinusitis with Nasal Polyps

Stock News
·
Aug 10

Keymed Biosciences: Phase II Trial of Bispecific Antibody CM512 Meets All Endpoints in Chronic Rhinosinusitis with Nasal Polyps

Bulletin Express
·
Aug 10

Keymed Biosciences Says Phase II Trial of CM512 Meets Endpoints in Chronic Rhinosinusitis with Nasal Polyps

Reuters
·
Aug 10

Keymed Biosciences Sets 19 Aug 2026 Board Meeting to Approve 1H26 Interim Results and Consider Dividend

Bulletin Express
·
Aug 07

Movement Alert|KEYMED BIO-B Rises 5.46% in Regular Trading, Multiple Institutions Cross 5% Threshold Amid Pipeline Catalysts

Market Focus
·
Aug 07

Orient Securities Company Limited Boosts Stake in Keymed Biosciences Inc with HK$14.8 Million Acquisition

Stock News
·
Aug 06

KEYMED BIO-B: DFZQ Acquires Shares, Long Position Rises to 5.05%

HK Disclosure
·
Aug 06